The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial.

Sai-Hong I. Ou, Marianna Koczywas, Susanna V. Ulahannan, Pasi Janne, Jose Pacheco, Howard A. Burris, Caroline McCoach, Judy S. Wang, Michael S. Gordon, Eric Haura, Jonathan W. Riess,  Viola Zhu,  Kimmie Ng,  S. Gail Eckhardt, Anna Capasso, Richa Dua, Ariel Chen, Zhengping Wang, Josie Hayes, Robert J. Nichols, Trever G. Bivona